Incorporating Demand and Supply Constraints into Economic Evaluations in Low‐Income and Middle‐Income Countries

Abstract Global guidelines for new technologies are based on cost and efficacy data from a limited number of trial locations. Country‐level decision makers need to consider whether cost‐effectiveness analysis used to inform global guidelines are sufficient for their situation or whether to use models that adjust cost‐effectiveness results taking into account setting‐specific epidemiological and cost heterogeneity. However, demand and supply constraints will also impact cost‐effectiveness by influencing the standard of care and the use and implementation of any new technology. These constraints may also vary substantially by setting. We present two case studies of economic evaluations of the introduction of new diagnostics for malaria and tuberculosis control. These case studies are used to analyse how the scope of economic evaluations of each technology expanded to account for and then address demand and supply constraints over time. We use these case studies to inform a conceptual framework that can be used to explore the characteristics of intervention complexity and the influence of demand and supply constraints. Finally, we describe a number of feasible steps that researchers who wish to apply our framework in cost‐effectiveness analyses.

[1]  Alan Shiell,et al.  Complex interventions: how “out of control” can a randomised controlled trial be? , 2004, BMJ : British Medical Journal.

[2]  Richard G. White,et al.  Using the TIME model in Spectrum to estimate tuberculosis–HIV incidence and mortality , 2014, AIDS.

[3]  Eric Obikeze,et al.  Cost-effectiveness analysis of rapid diagnostic test, microscopy and syndromic approach in the diagnosis of malaria in Nigeria: implications for scaling-up deployment of ACT , 2009, Malaria Journal.

[4]  S. Dorman,et al.  Optimal Triage Test Characteristics to Improve the Cost-Effectiveness of the Xpert MTB/RIF Assay for TB Diagnosis: A Decision Analysis , 2013, PloS one.

[5]  V. Wiseman,et al.  Designing and implementing interventions to change clinicians’ practice in the management of uncomplicated malaria: lessons from Cameroon , 2014, Malaria Journal.

[6]  A. Gheorghe,et al.  The need for increased harmonisation of clinical trials and economic evaluations , 2014, Expert review of pharmacoeconomics & outcomes research.

[7]  Richard G. White,et al.  Modeling of Novel Diagnostic Strategies for Active Tuberculosis – A Systematic Review: Current Practices and Recommendations , 2014, PloS one.

[8]  Richard Grieve,et al.  Statistical Methods for Cost-Effectiveness Analyses That Use Data from Cluster Randomized Trials , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[9]  Chantal Morel,et al.  Cost-effectiveness of malaria diagnostic methods in sub-Saharan Africa in an era of combination therapy. , 2008, Bulletin of the World Health Organization.

[10]  F. Masiye,et al.  Cost-effectiveness analysis of the available strategies for diagnosing malaria in outpatient clinics in Zambia , 2009, Cost effectiveness and resource allocation : C/E.

[11]  V. Wiseman,et al.  Basic or enhanced clinician training to improve adherence to malaria treatment guidelines: a cluster-randomised trial in two areas of Cameroon. , 2014, The Lancet. Global health.

[12]  Vikram Patel,et al.  Theory of Change: a theory-driven approach to enhance the Medical Research Council's framework for complex interventions , 2014, Trials.

[13]  C. Rogier,et al.  Use of HRP-2-based rapid diagnostic test for Plasmodium falciparum malaria: assessing accuracy and cost-effectiveness in the villages of Dielmo and Ndiop, Senegal , 2010, Malaria Journal.

[14]  Angel Rosas-Aguirre,et al.  Relación costo-efectividad del uso de pruebas rápidas para el diagnóstico de la malaria en la Amazonia peruana , 2009 .

[15]  S. Lawn,et al.  Effect of empirical treatment on outcomes of clinical trials of diagnostic assays for tuberculosis. , 2015, The Lancet. Infectious diseases.

[16]  J. Ndiaye,et al.  Major Reduction in Anti-Malarial Drug Consumption in Senegal after Nation-Wide Introduction of Malaria Rapid Diagnostic Tests , 2011, PloS one.

[17]  S. Basu,et al.  Comparing Decisions for Malaria Testing and Presumptive Treatment , 2014, Medical decision making.

[18]  V. Wiseman,et al.  Economic evaluation of a cluster randomized trial of interventions to improve health workers' practice in diagnosing and treating uncomplicated malaria in Cameroon. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  C. Whitty,et al.  The cost-effectiveness of parasitologic diagnosis for malaria-suspected patients in an era of combination therapy. , 2007, The American journal of tropical medicine and hygiene.

[20]  R. Grieve,et al.  Using multilevel models for assessing the variability of multinational resource use and cost data. , 2005, Health economics.

[21]  W. MacLeod,et al.  The Impact and Cost of Scaling up GeneXpert MTB/RIF in South Africa , 2012, PloS one.

[22]  Ted Cohen,et al.  Assessment of the patient, health system, and population effects of Xpert MTB/RIF and alternative diagnostics for tuberculosis in Tanzania: an integrated modelling approach. , 2014, The Lancet. Global health.

[23]  Eduardo Gotuzzo,et al.  Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study , 2011, The Lancet.

[24]  J. Eaton,et al.  A Side Door Into Care Cascade for HIV-Infected Patients? , 2013, Journal of acquired immune deficiency syndromes.

[25]  Grant Theron,et al.  Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial , 2014, The Lancet.

[26]  Grant Russell,et al.  Patient-centred access to health care: conceptualising access at the interface of health systems and populations , 2013, International Journal for Equity in Health.

[27]  C. Fraser,et al.  The potential effects of changing HIV treatment policy on tuberculosis outcomes in South Africa: results from three tuberculosis-HIV transmission models , 2014, AIDS.

[28]  R. Snow,et al.  Modeling the financial and clinical implications of malaria rapid diagnostic tests in the case-management of older children and adults in Kenya. , 2008, The American journal of tropical medicine and hygiene.

[29]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[30]  K. Indaratna,et al.  Determining cost-effectiveness and cost component of three malaria diagnostic models being used in remote non-microscope areas. , 2003, The Southeast Asian journal of tropical medicine and public health.

[31]  H. Tinto,et al.  Strict adherence to malaria rapid test results might lead to a neglect of other dangerous diseases: a cost benefit analysis from Burkina Faso , 2011, Malaria Journal.

[32]  C. Whitty,et al.  Cost-Effectiveness Analysis of Introducing RDTs for Malaria Diagnosis as Compared to Microscopy and Presumptive Diagnosis in Central and Peripheral Public Health Facilities in Ghana , 2013, The American journal of tropical medicine and hygiene.

[33]  B. Marston,et al.  Cost-Effectiveness of Tuberculosis Diagnostic Strategies to Reduce Early Mortality Among Persons With Advanced HIV Infection Initiating Antiretroviral Therapy , 2012, Journal of acquired immune deficiency syndromes.

[34]  R. Walensky,et al.  The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy: a model-based analysis , 2012, AIDS.

[35]  A. Vassall,et al.  Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review , 2015, PharmacoEconomics.

[36]  K. Barnes,et al.  Should countries implementing an artemisinin-based combination malaria treatment policy also introduce rapid diagnostic tests? , 2008, Malaria Journal.

[37]  N. Ford,et al.  Strength of recommendations in WHO guidelines using GRADE was associated with uptake in national policy. , 2015, Journal of clinical epidemiology.

[38]  H-H Lin,et al.  A modelling framework to support the selection and implementation of new tuberculosis diagnostic tools [State of the art series. Operational research. Number 8 in the series]. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[39]  John Stover,et al.  Towards an improved investment approach for an effective response to HIV/AIDS , 2011, The Lancet.

[40]  J. Stover,et al.  Methods used in the Lives Saved Tool (LiST) , 2011, BMC public health.

[41]  F. Pang,et al.  Generalisability in economic evaluation studies in healthcare: a review and case studies. , 2004, Health technology assessment.

[42]  F. Checchi,et al.  Operational response to malaria epidemics: are rapid diagnostic tests cost‐effective? , 2006, Tropical medicine & international health : TM & IH.

[43]  R. Atun,et al.  Integration of targeted health interventions into health systems: a conceptual framework for analysis. , 2010, Health policy and planning.

[44]  B. Hamainza,et al.  Relative costs and effectiveness of treating uncomplicated malaria in two rural districts in Zambia: implications for nationwide scale-up of home-based management , 2011, Malaria Journal.

[45]  Anne Mills,et al.  The impact of response to the results of diagnostic tests for malaria: cost-benefit analysis , 2008, BMJ : British Medical Journal.

[46]  B. Uzochukwu,et al.  Effectiveness of Provider and Community Interventions to Improve Treatment of Uncomplicated Malaria in Nigeria: A Cluster Randomized Controlled Trial , 2015, PloS one.

[47]  A. Dia,et al.  Évaluation économique des tests de diagnostic rapide dans le traitement du paludisme , 2010 .

[48]  P. Vickerman,et al.  Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments , 2016, Health economics.

[49]  Grant Theron,et al.  Do adjunct tuberculosis tests, when combined with Xpert MTB/RIF, improve accuracy and the cost of diagnosis in a resource-poor setting? , 2011, European Respiratory Journal.

[50]  C. Whitty,et al.  An interactive model for the assessment of the economic costs and benefits of different rapid diagnostic tests for malaria , 2008, Malaria Journal.

[51]  M. Sudhinaraset,et al.  Cost-effectiveness analysis of malaria rapid diagnostic test incentive schemes for informal private healthcare providers in Myanmar , 2015, Malaria Journal.

[52]  F. Althaus,et al.  Over-diagnosis of malaria by microscopy in the Kilombero Valley, Southern Tanzania: an evaluation of the utility and cost-effectiveness of rapid diagnostic tests , 2013, Malaria Journal.

[53]  Christopher Dye,et al.  Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. , 2015, The Lancet. Global health.

[54]  Alan Shiell,et al.  Complex interventions or complex systems? Implications for health economic evaluation , 2008, BMJ : British Medical Journal.

[55]  C. Lengeler,et al.  Cost Savings with Rapid Diagnostic Tests for Malaria in Low-Transmission Areas: Evidence from Dar es Salaam, Tanzania , 2010, The American journal of tropical medicine and hygiene.

[56]  Andrea Manca,et al.  Increasing the generalizability of economic evaluations: Recommendations for the design, analysis, and reporting of studies , 2005, International Journal of Technology Assessment in Health Care.

[57]  M. R. F. de Oliveira,et al.  Cost-effectiveness of diagnostic for malaria in Extra-Amazon Region, Brazil , 2012, Malaria Journal.

[58]  M. Rowland,et al.  Cost-effectiveness of malaria diagnosis using rapid diagnostic tests compared to microscopy or clinical symptoms alone in Afghanistan , 2015, Malaria Journal.

[59]  Max O Bachmann,et al.  Cost‐effectiveness of nurse‐led versus doctor‐led antiretroviral treatment in South Africa: pragmatic cluster randomised trial , 2013, Tropical medicine & international health : TM & IH.

[60]  D. Dowdy,et al.  Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? , 2014, The Lancet. Infectious diseases.

[61]  Andrew R Willan,et al.  'Lost in translation': accounting for between-country differences in the analysis of multinational cost-effectiveness data. , 2006, PharmacoEconomics.

[62]  P. Magnussen,et al.  Cost-effectiveness of malaria microscopy and rapid diagnostic tests versus presumptive diagnosis: implications for malaria control in Uganda , 2011, Malaria Journal.

[63]  P. Palange,et al.  From the authors , 2007, European Respiratory Journal.

[64]  R. Atun,et al.  A systematic review of the evidence on integration of targeted health interventions into health systems. , 2010, Health policy and planning.

[65]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[66]  J. Salomon,et al.  Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic Evaluation , 2012, PLoS medicine.

[67]  Anna Vassall,et al.  Rapid Diagnosis of Tuberculosis with the Xpert MTB/RIF Assay in High Burden Countries: A Cost-Effectiveness Analysis , 2011, PLoS medicine.

[68]  M. San Sebastiån,et al.  Cost-effectiveness of three malaria treatment strategies in rural Tigray, Ethiopia where both Plasmodium falciparum and Plasmodium vivax co-dominate , 2011, Cost effectiveness and resource allocation : C/E.

[69]  M. R. F. de Oliveira,et al.  Cost effectiveness of OptiMal® rapid diagnostic test for malaria in remote areas of the Amazon Region, Brazil , 2010, Malaria Journal.

[70]  A. Dia,et al.  [Economic evaluation of rapid diagnostic tests in malaria treatment]. , 2010, Sante publique.